Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline
PTEN
Mutations
JCO Precis Oncol
.
2019 Dec 5:3:PO.19.00130.
doi: 10.1200/PO.19.00130.
eCollection 2019.
Authors
Belinda Kingston
1
,
Caroline Bailleux
2
,
Suzette Delaloge
2
2
,
Gaia Schiavon
3
,
Veronique Scott
2
,
Magali Lacroix-Triki
2
2
,
T Hedley Carr
3
,
Iwanka Kozarewa
3
,
Heidrun Gevensleben
4
,
Zoe Kemp
5
,
Alex Pearson
1
,
Nicholas Turner
1
5
,
Fabrice André
2
Affiliations
1
Institute of Cancer Research, London, United Kingdom.
2
Institut Gustave Roussy, Villejuif, France.
3
AstraZeneca, IMED Oncology, Cambridge, United Kingdom.
4
Bonn University Hospital, Bonn, Germany.
5
The Royal Marsden NHS Foundation Trust, London, United Kingdom.
PMID:
32923864
PMCID:
PMC7446515
DOI:
10.1200/PO.19.00130
No abstract available
Publication types
Case Reports